This technology has the potential to be used as combination therapeutics for breast cancer treatments.

About

Description Novel Hsp90 Inhibitors for Breast Cancer Treatment  Advantage of Invention Researchers at GRU discovered that beauvericin and its certain derivatives are very effective inhibitors of Hsp90 and the inhibition does not generate heat shock responses (i.e. do not overexpress Hsp70 and Hsp27). This technology has the potential to be used as combination therapeutics for breast cancer treatments. 

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations